长春瑞滨抗肿瘤的药物经济学研究  

Study on Pharmacoeconomics of Vinorelbine for Treating Tumor

作　　者：温明铃[1] 杨 丁桥兰[1] 高晖[1] 

机构地区：[1]军事医学科学院附属医院药剂科,北京100039

出　　处：《中国药业》2006年第1期51-52,共2页China Pharmaceuticals

摘　　要：目的:对抗肿瘤药物长春瑞滨的临床疗效进行经济学评价,为临床提供用药参考。方法:回顾性分析军事医学科学院附属医院44例肿瘤患者使用国产和进口长春瑞滨的情况,采用最小成本法对NP方案(长春瑞滨+顺铂)进行经济学评价。结果:两种长春瑞滨在疗效方面没有显著性差异,但在经济成本上差异显著。结论:国产长春瑞滨在有针对性的化疗新方案中,是安全、有效、经济的抗肿瘤药物。Objective： To evaluate the clinical efficacy of vinorelbine with pharmacoeconomics in order to supply references for clinician in drug usage. Methods： To retrospectively analyze 44 cases on the application of vinorelbine in therapeutic scheme of NP（vinorelbine ＋ DDP） and to evaluate the economic effectiveness with minimized cost analysis. Results： There was no significant difference between the two kinds of vinorelbine in term of clinical cure rate, while significant difference was existed in the cost. Conclusion： Domestic inhaled vinorelbine was a more safe, economic and effective drug.

关 键 词：长春瑞滨 疗效评价 药物经济学 

分 类 号：F407.7[经济管理—产业经济] R978.1[医药卫生—药品]